drugset

drugset / Trial / NCT00370682

A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand

NCT00370682 ↗

Phase 2 Completed 120 enrolled U.S. Army Medical Research and Development Command GlaxoSmithKline · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

This descriptive study will evaluate the safety and immunogenicity of different formulations of the WRAIR dengue vaccine compared to a placebo.

Timeline

Start: 2007-04
Primary completion: 2008-02
Completion: 2008-02

Publications

Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A, Tournay E, De La Barrerra R, Dessy F, Toussaint JF, Eckels KH, Thomas SJ, Innis BL. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg. 2014 Jul;91(1):119-28. doi: 10.4269/ajtmh.13-0452. Epub 2014 May 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	T-DEN F-19	Vaccine	0.5 ml	Subcutaneous
Subject	T-DEN F17	Vaccine	0.5 ml	Subcutaneous

Indications